Navigation Links
Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011
Date:11/3/2011

through the "Investor Relations" section of the Sequenom website at www.sequenom.com.  An online replay will be available following the initial broadcast until Thursday, December 1, 2011.  

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions.  Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and clinical molecular diagnostics markets.  The Company was founded in 1994 and is headquartered in San Diego, California.  Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom.  Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

SEQUENOM®, Sequenom CMM®, MaterniT21™, SensiGene®, SEQureDx™, RetnaGene™ and MassARRAY® are trademarks of Sequenom, Inc.  

About Sequenom Center for Molecular Medicine
Sequenom Center for Molecular Medicine (Sequenom CMM®) has two CAP accredited and CLIA-certified molecular diagnostics reference laboratories dedicated to the development and commercialization of laboratory developed test for prenatal and eye conditions and diseases.  Utilizing innovative proprietary technologies, Sequenom CMM provides test results that can be used as tools by clinicians in managing patient care.  Testing services are available only upon request to physicians.  Sequenom CMM works cl
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Sequenom, Inc. Announces Date of Second Quarter 2011 Financial Results and Conference Call
2. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
3. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
4. Par Pharmaceutical Reports Second Quarter 2008 Results
5. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
6. Pharmos Corporation Reports 2008 Second Quarter Results
7. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
8. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
9. BMP Sunstone Reports Second Quarter 2008 Financial Results
10. ULURU Inc. Reports Second Quarter 2008 Financial Results
11. Immtech Reports Fiscal First Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
(Date:5/21/2015)... - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: ... on the development of autologous cell therapies, announced ... Society for Cellular Therapy (ISCT) on RepliCel,s autologous ... a Phase 1/2 clinical trial.  The presentation, taking ... PM to 7:00 PM local time, will review ...
(Date:5/20/2015)... , May 20, 2015 ... presented preliminary data demonstrating the ability of the ... fibrosis (IPF) from other interstitial lung diseases (ILDs) ... the classifier,s potential to help thousands of patients ... ambiguity in IPF diagnosis – a frequent challenge ...
(Date:5/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) has ... Market Outlook 2020 " report to their offering. ... regenerative medicine is expected to have huge marketing potential. ... in the growth of deregulated organs. Several therapeutic molecules ... to form new tissue or sometimes organ transplant is ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
... , ATLANTA, Aug. 5 GeoVax Labs, Inc. ... today announced updates on its ongoing and planned human clinical trials. ... areas of focus for our HIV/AIDS vaccine - preventative and therapeutic," ... Labs, Inc. "The results of the early Phase 1 clinical ...
... , SAINT JOHN, New Brunswick, ... between nuclear reactors and thyroid disease near NYC was made ... festival is held just downstream from Indian Point, the oldest ... commitment to a clean environment, it stepped up by permitting ...
... 5 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a ... with UK-based Scancell Ltd., the operating company of ... cancer and infectious disease vaccines. This research agreement ... delivery system for Scancell,s novel ImmunoBody(R) DNA vaccines. ...
Cached Biology Technology:GeoVax Labs, Inc. Provides Clinical Studies Update 2GeoVax Labs, Inc. Provides Clinical Studies Update 3GeoVax Labs, Inc. Provides Clinical Studies Update 4GeoVax Labs, Inc. Provides Clinical Studies Update 5TSH Testing Raises Awareness of Importance of Thyroid Health 2ImmunoVaccine Technologies Partners With Scancell to Advance DNA Vaccine Delivery 2
(Date:5/18/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
(Date:5/11/2015)... Calif. , May 11, 2015  Synaptics ... of human interface solutions, today announced the appointment ... President and Chief Financial Officer, reporting to ... replaces Synaptics, current Chief Financial Officer, Kathleen ... 2014. Mr. Ali brings extensive ...
(Date:5/10/2015)... Sweden , May 11, 2015 ... fingerprint sensors FPC1025 and FPC1155 from the distributor World Peace ... of FPC,s distributors in Asia . Deliveries ... sensors will be used by smartphone manufacturers in ... included in the communicated revenue guidance of + 1 000 MSEK ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... Beyond the simple stream of one-letter characters in the ... In order to decipher this level of architecture, scientists ... detect copy number variants (CNVs)--defined as large deletions and ... the journal Genome Research --were used to create ...
... behind the dramatic increase in testicular cancer, now ... men, is the focus of a five-year, $5.5 ... Public Health researcher Tongzhang Zheng. , Testicular cancer ... will provide important information on possible environmental, genetic ...
... Helping to change scientists' thinking about how the heart is ... of stem cell that is the precursor to at least ... cardiac progenitor cell gives rise to both myocardial cells, which ... heart, and to the vascular smooth muscle cells that line ...
Cached Biology News:New technology used to construct the first map of structural variation in the human genome 2Getting to the heart of the heart 2Getting to the heart of the heart 3
Request Info...
Mouse monoclonal [3G131] to Desmoglein 1 ( Abpromise for all tested applications). entrezGeneID: 1828 SwissProtID: Q02413...
TCP-1 alpha (H-110)...
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: